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Enteroendocrine cells are sensory cells located in the intestinal epithelium that produce a variety of 
hormonal regulators of gastrointestinal physiology, metabolism and food intake. They detect the 
absorption of a wide range of ingested nutrients via pathways that include transporter-mediated 
uptake, G-protein coupled receptors and ion channels. This review will describe mechanisms by 
which the L-cells that produce Glucagon Like Peptide-1 (GLP-1) respond to different components of 
ingested food, and the importance of these pathways not only for understanding physiology, but 
also for developing new treatments for type 2 diabetes and obesity. 
 
Introduction 
Enteroendocrine cells comprise 0.1 to 1% of the gut epithelium, and produce hormones that 
orchestrate the body’s response to food ingestion. Although originally identified as regulators of 
gastrointestinal processes such as gall bladder contraction and pancreatic enzyme secretion, gut 
hormones also play important roles in the control of metabolism, being the first step in a gut-brain-
pancreatic axis. As enteroendocrine cells directly face into the intestinal lumen, they are ideally 
placed to detect the composition of ingested food, the rate of nutrient absorption and the products 
of intestinal microbial metabolism. This review will discuss mechanisms by which enteroendocrine 
cells sense the luminal contents, and the importance of gut hormones for metabolic physiology and 
disease.     
 Enteroendocrine cells and their metabolic importance  
Enteroendocrine cells are located along the length of the intestinal epithelium from the stomach to 
the rectum. They have classically been divided into sub-populations, each classified according to 
their production of one or a few distinct hormonal products. K-cells, for example, are predominantly 
located in the duodenum and produce glucose-dependent insulinotropic polypeptide (GIP), whereas 
L-cells are located in higher numbers in the distal small intestine and colon and primarily produce 
glucagon-like peptide-1 (GLP-1) and peptideYY (PYY) [1]. Enteroendocrine cells are formed together 
with the other epithelial cell types by continuous stem cell division in the crypts, and have a life span 
of 3-5 days in the small intestine [2]. Recent literature suggests that there is a high degree of 
transcriptional overlap between different enteroendocrine cell populations [3, 4], and it remains 
uncertain whether the hormonal signatures of individual cells are determined predominantly by 
their location along the gastrointestinal axis, or whether they are also significantly influenced by diet 
and the metabolic state.   
The most studied of the metabolically active gut hormones is GLP-1, which was identified alongside 
GIP as a physiological incretin hormone [5]. The action of incretin hormones underlies 50-70% of 
insulin secretion after a meal and arises because GLP-1 and GIP are secreted as glucose is absorbed 
in the gastrointestinal (GI) tract, and amplify glucose-stimulated insulin secretion from pancreatic 
beta cells [6]. In the early 1990’s it was shown that GLP-1 is an effective stimulus of insulin secretion 
even in patients with type 2 diabetes [7], a finding that led to the development of GLP-1 analogues 
and inhibitors of GLP-1 degradation (DPP4 inhibitors) for the treatment of 2 diabetes and obesity. As 
a treatment, GLP-1 analogues have many desirable effects, including stimulation of insulin release, 
appetite suppression, inhibition of glucagon secretion and slowing of gastric emptying [8]. Some 
GLP-1 mimetics have also recently been shown to reduce the frequency of cardiovascular events in 
high risk patients with type 2 diabetes [9]. 
As well as enhancing insulin secretion, another major role of the gut endocrine axis is to control food 
intake. Whereas the most proximally located hormone affecting appetite is Ghrelin [10] – an 
orexigenic hormone released from the stomach epithelium – the majority of gut hormones are 
anorexigenic. In the proximal gut CCK has profound inhibitory effects on food intake, likely mediated 
by signalling through the afferent vagus [11]. GLP-1 and PYY are released when nutrients penetrate 
more distal regions of the small intestine, and further suppress appetite. The exact sites of 
physiological GLP-1 and PYY detection remain controversial, but receptors for PYY detection have 
been located in the hypothalamus [12], and GLP-1 detection has been observed at a variety of stages 
of the afferent vagus/brainstem/hypothalamus circuitry [13, 14].  
Methods for studying signalling in EECs with focus on L-cells 
Early studies investigating signalling pathways in EECs used the murine cell lines GLUTag and STC-1. 
GLUTag cells are a colonic tumour cell line producing the hormones GLP-1 and CCK, but not PYY [15, 
16]. This pattern doesn’t exactly match that of colonic L-cells which produce GLP-1 and PYY but only 
little CCK [3], but a large body of evidence suggests that they are a good model of mouse L-cells. STC-
1 cells were derived from a small intestinal tumour, and produce a number of hormones, including 
GLP-1, CCK, secretin and GIP [17]. The plurihormonal nature of STC-1 cells originally raised concerns 
that this cell line might represent immature and incompletely differentiated EECs. Recent data, 
however, highlight that native small intestinal EECs are also plurihormonal [3, 4], so STC-1 might, 
after all, be a valid model of small intestinal EECs.  
To circumvent the drawbacks of working with cell lines, we and a number of groups made transgenic 
reporter mice in which different EEC populations are labelled with fluorescent reporters and sensors, 
driven by cell-specific hormonal promoters [18, 19]. These mouse lines enable the purification and 
characterisation by single cell imaging of native enteroendocrine cells, and have led to a much 
deeper understanding of how EECs respond to different stimuli. Transcriptomic comparisons 
between cell populations labelled using different hormonal promoters have highlighted the 
similarities between enteroendocrine cell types that were classically supposed to be distinct, 
revealing that EEC sub-populations are highly overlapping and potentially exhibit plasticity in their 
hormonal signatures [3, 4, 20, 21]. CCK, for example, is traditionally viewed as a marker of I-cells, but 
was also detected at high levels in K-cells and L-cells [18, 19], suggesting that stimuli that increase 
secretion of GLP-1 and GIP will also enhance CCK release.  Despite the overlapping expression 
profiles of EECs producing different hormones, each hormone exhibits a distinct post-prandial 
plasma profile that varies according to the meal composition. GLP-1 secretion is often separated into 
early and late phases, and some evidence supports the idea that the early post-prandial rise in GLP-1 
and PYY levels reflects a neural circuit that activates L-cells located in the distal gut [22]. However, it 
has more recently been established that enough GLP-1-producing cells are located in the proximal 
human gut to account for the observed early peak of secretion [23], and the temporal changes in the 
plasma concentration of each gut hormone after a meal are likely dominated by a complex interplay 
between the location of enteroendocrine cells producing that hormone, the sensory machinery they 
express, and the sites of nutrient absorption.  
Basic properties of Enteroendocrine cells 
Enteroendocrine cell lines and primary colonic L-cells are electrically active, firing action potentials 
carried by voltage gated sodium and calcium channels [24-27]. A number of nutrients, including 
glucose and amino acids, trigger membrane depolarisation and increased action potential firing [28, 
29]. This is associated with the influx of calcium through voltage gated Ca2+ currents, elevation of 
intracellular Ca2+ concentrations, and consequent stimulation of vesicle exocytosis [30]. Studies in 
GLUTag cells suggested that inhibition of voltage gated Na+ channels using tetrodotoxin blocked 
action potential firing but did not impair glucose-triggered GLP-1 secretion, suggesting that action 
potentials might not be critical for hormone release [24]. In primary colonic L-cells, however, TTX 
both impaired glutamine-triggered GLP-1 release and slowed action potential firing [25]. As action 
potentials in primary L-cells were not completely abolished by TTX, the remaining electrical activity is 
likely dependent on voltage gated Ca2+ currents. Further experiments including inhibitors of P/Q, L, N 
and T-type Ca2+ channels will be required before conclusions can be drawn regarding the importance 
of action potentials for enteroendocrine cell secretion. 
Enteroendocrine cells also express a variety of G-protein coupled receptors that are important for 
linking hormone secretion to a variety of nutritional and hormonal stimuli. Receptors that activate 
Gq proteins elevate intracellular Ca
2+ by IP3-dependent release from intracellular stores [31]. In 
addition, however, our data suggest that some Gq-coupled receptors, such as the calcium sensing 
receptor (CASR) and free fatty acid receptor-1 (FFAR1), recruit voltage gated Ca2+ entry in 
enteroendocrine cells through the activation of transient receptor potential (TRP) channels [32, 33]. 
In the case of FFAR1, Ca2+ responses to the ligand GW9508 in L-cells were abolished by the specific 
TRPC3 channel blocker Pyr3, suggesting that activation of this Gq coupled receptor can result in 
membrane depolarisation via TRPC3 opening, which in turn leads to voltage gated Ca2+ channel entry 
[33].  
Activation of Gs coupled receptors in L-cells can also trigger small Ca
2+ responses in L-cells. In the 
GLUTag cell model, cAMP was found to increase the activity of hyperpolarisation activated currents 
and to close a background potassium conductance, both of which effects resulted in enhanced 
membrane excitability and increased responsiveness to glucose [34]. The relative importance of 
these mechanisms in primary enteroendocrine cells remains to be elucidated. 
Mechanisms of intestinal chemosensation:  
Glucose sensing: 
In perfused intestine experiments, luminally-applied glucose or non-metabolisable glucose 
analogues were found to trigger GLP-1 secretion as long as the sugars were substrates of the brush 
border glucose uptake pathway and applied in the presence of Na+ ions [35, 36]. Both glucose 
uptake and GLP-1 secretion are blocked by phloridzin, an inhibitor of sodium-coupled glucose 
transporters, SGLT1, that are responsible for active glucose absorption across the apical epithelial 
surface. These findings suggest that glucose must be absorbed across the brush border in order to 
trigger GLP-1 secretion, but do not identify the reason why. Several potential explanations are 
possible: a) Glucose might be sensed on the basolateral membrane of L-cells, and only therefore be 
effective after absorption; b) Glucose might be detected by an intracellular sensor and thus require 
entry across the apical membrane; and c) The process of glucose absorption might itself act as a 
sensory pathway.  
A number of experiments argue against the idea that glucose is sensed on the basolateral membrane 
of L-cells. In classical assessments of the incretin effect in humans, responses to an oral glucose 
bolus have been compared with those produced by an intravenous infusion designed to produce a 
matched plasma glucose profile. In these studies, plasma GLP-1 and GIP concentrations were 
elevated after oral but not intravenous glucose, suggesting that the enteroendocrine cell glucose 
sensor is located on the apical rather than the basolateral membrane surface [37]. Glucose-triggered 
GLP-1 secretion has also been demonstrated in primary intestinal cultures, where glucose had 
unrestricted access to basolateral as well as apical cell membranes [19]. As in the perfused intestine, 
GLP-1 secretion from primary cultures was blocked by phloridzin or global SGLT1 knockout [38, 39], 
even though these interventions would not influence glucose concentrations at the basolateral 
membrane in cell cultures, again arguing against the concept of a critical basolaterally located 
receptor. The possibility has been raised that glucose might be detected by L-cell sweet taste 
receptors, but we have been unable to detect significant expression of components of the sweet 
taste receptor pathway in L-cells [19], and most physiological studies have found very little response 
to sweet tastants in humans and animals [40, 41]. Taken together, these findings do not support the 
existence of an L-cell glucose receptor pathway located basolaterally in the intestinal epithelium. 
To investigate whether SGLT1 acts by concentrating glucose inside the L-cell where it might be 
sensed by an intracellular signalling pathway, we imaged cytoplasmic glucose concentrations using a 
FRET-based glucose sensor. In GLUTag and primary L-cells, phloridzin blocked GLP-1 secretion, but 
did not impair the cytoplasmic glucose signal observed after increasing extracellular glucose 
concentrations. By contrast, phloretin, a general inhibitor of facilitative glucose transporters 
(GLUTs), prevented the cytoplasmic glucose rise triggered by extracellular glucose, but did not impair 
glucose-dependent GLP-1 release [39]. These findings suggest that the L-cell glucose sensor is largely 
dissociated from glucose concentrations inside the cell, making the concept of a cytoplasmically 
located glucose sensor unlikely. 
The third idea, that the apical SGLT1 transporter is directly linked to GLP-1 secretion, is supported by 
a large body of evidence, including that SGLT1 knockout and SGLT1 inhibitors block GLP-1 and GIP 
secretion in both in vitro and in vivo systems [38, 39]. Whilst we cannot be certain exactly how the 
interaction of glucose with SGLT1 stimulates gut hormone secretion, glucose triggered a small but 
measurable sodium-dependent inward current and corresponding membrane depolarisation in 
GLUTag cells, likely due to the coupled uptake of 2Na+ ions with each glucose molecule [27]. In our 
working model of the L-cell, we proposed that the depolarising effect of the Na+ ions that 
accompany glucose influx are responsible for membrane depolarisation, voltage gated Ca2+ entry 
and triggering of vesicular exocytosis. This idea is supported by mathematical modelling that takes 
into account the measured magnitudes of SGLT1 and voltage-dependent currents in GLUTag and L-
cells [42]. 
Fat sensing: 
Ingested fat is emulsified with bile acids and enzymatically hydrolysed to release free fatty acids and 
monoacylglyerols. Each of these components - long chain fatty acids, monoacylglycerols and bile 
acids – activates distinct sensory pathways in enteroendocrine cells. Unlike glucose sensing, the 
majority of fat sensing likely involves the activation of G-protein coupled receptors (GPCRs). 
Long chain fatty acid sensing in L-cells has been most strongly linked to the activation of GPR40 
(FFAR1), with a possible contribution from GPR120 (FFAR4) [33]. Both are predominantly Gq-
coupled receptors, although there have been some reports of Gi pathways being activated 
downstream of GPR120 [43], and of some GPR40 ligands activating Gs [44]. GPR40 ligands elevate 
Ca2+ concentrations in I-cells and L-cells [33, 45], but this does not seem entirely dependent on Ca2+ 
release from intracellular stores, as there are many reports of fatty acid triggered Ca2+ signals being 
blocked by inhibitors of voltage gated Ca2+ channels [33]. In L-cells we demonstrated the GPR40-
dependent activation of TRPC3, as has also been reported in pancreatic beta cells [33, 46]. 
Interestingly, as described for glucose above, fatty acid absorption across the epithelial layer seems 
critical for GLP-1 secretion by ingested fat, as small molecule GPR40 ligands were found to be 
effective when applied via the vasculature but not via the lumen when applied in the perfused 
intestinal model [47].  
Mono-oleoylglycerols are detected by GPR119 – another receptor found highly expressed and 
enriched in the enteroendocrine cell population [18, 19, 48]. GPR119 is predominantly Gs coupled, 
linked to the elevation of cytoplasmic cAMP concentrations in L-cells [49]. GPR119 seems 
particularly important for GLP-1 release, as L-cell specific Gpr119 knockout in mice almost 
completely abolished the plasma GLP-1 rise triggered by oral triglycerides [49]. Although agonists of 
GPR119 elevated GLP-1 levels in mice, they were less effective in humans and the metabolic effects 
of activating this receptor were pronounced only in the rodent models [50-52]. The reason for their 
low effectiveness in humans is unclear, but studies on primary intestinal cultures suggested that 
even in mice, GPR119 ligands only increased cAMP concentrations in ~50% of L-cells [49]. Whether 
this percentage is similar or lower in human compared with murine L-cells remains to be established. 
Studies to examine whether GPR119 is located on the apical or basolateral membrane have 
concluded that it is accessible from both directions [53, 54].  
Bile acids activate an L-cell enriched G-protein coupled receptor known as TGR5, or GPBAR1. 
GPBAR1 is a Gs coupled receptor linked to robust elevation of cAMP and a strong GLP-1 secretory 
response in primary L-cells from mouse and human [55]. Like GPR40, ligands of GPBAR1 seem to 
have to cross the epithelial layer before they are able to trigger GLP-1 secretion. Application of apical 
bile acids in Ussing chambers, for example, triggered GLP-1 secretion that was prevented when bile 
acid absorption was inhibited by blockade of the apical sodium coupled bile acid transporter, ASBT, 
yet ASBT inhibition did not affect bile acid triggered GLP-1 secretion from primary cultures with free 
access to both membrane compartments. In agreement with this finding, a specific GPBAR1 ligand 
triggered GLP-1 secretion when applied to the basolateral but not the apical compartment in Ussing 
chambers [55].  
Protein sensing: 
Enteroendocrine cell sensing of ingested protein seems to involve a variety of transporters and 
receptors, and resembles aspects of both glucose and fat sensing. Amino acid uptake across the 
brush border involves a variety of transporters, many of which take advantage of the inwardly 
directed Na+ gradient to drive amino acid absorption against a concentration gradient. As found for 
SGLT1, we detected small glutamine and asparagine-dependent inward currents in GLUTag cells, 
that were abolished in the absence of Na+ ions and likely reflected the activity of a sodium coupled 
transporter such as ATA2 (Slc38a2) [28]. Another transporter, PEPT1, harnesses the inwardly-
directed proton gradient to drive uptake of di and tri-peptides. Mice lacking Pept1 exhibited 
impaired GLP-1 release in primary cultures [56]. It therefore appears that a number of amino acids 
and di/tri peptides are likely capable of triggering gut hormone release as a consequence of ion-
coupled uptake across the apical membrane, which in turn leads to membrane depolarisation and 
voltage gated Ca2+ entry. 
In addition to these depolarising uptake pathways, amino acids and oligopeptides have been found 
to activate calcium sensitive receptors (CASR) and GPR142 in primary L-cells [56-58]. CASR is a 
predominantly Gq-coupled receptor that in L-cells has been linked to the detection of 
phenylalanine, glutamine and peptones [32, 56, 57]. Its activation in primary L-cells triggers a robust 
Ca2+ signal that is dependent on TRP-channel mediated membrane depolarisation [32]. A related 
receptor, GPRC6A, has been implicated in the detection of ornithine by GLUTag cells, but is only 
poorly expressed in mouse primary L-cells [59]. GPR142 has been implicated in tryptophan and 
phenylalanine sensing by enteroendocrine cells [58]. The localisation of these amino acid sensing 
receptors on enteroendocrine cells remains to be established. 
Although Pept1 knockout resulted in minor impairment of secretion in vitro, the effects of CASR on 
GLP-1 release appear larger and have been observed using a variety of experimental approaches [56, 
57]. It is interesting that CASR and GPR142 are more strongly activated by the essential aromatic 
amino acids and the conditionally essential amino acid glutamine. The utilisation by L-cells of these 
receptors for amino acid sensing suggests that the gut endocrine system might be particularly tuned 
to detecting the ingestion of these essential and conditionally essential amino acids.  
L-cell cross talk with the colonic microbiome 
Under most circumstances, the digestion and absorption of ingested nutrients is completed within 
the proximal small intestine, and the colon should not receive much digestible food from the diet. 
Colonic microbiota will, however, metabolise a variety of substrates, including dietary fibre and bile 
acids, and even if ingested nutrients are efficiently absorbed higher up the intestinal tract, epithelial 
cell turnover results in persistent loss of dead cells into the gut lumen, which can act as an additional 
food source for colonic microbiota. A number of metabolites produced by gut microbiota have been 
linked to changes in GLP-1 secretion, including short chain fatty acids, indole and secondary bile 
acids [55, 60, 61].  
Short chain fatty acids can influence cellular activity through a variety of signalling pathways, but the 
receptor most strongly linked to GLP-1 secretion is GPR43 (FFAR2) [60, 62]. This is a Gi/q coupled 
receptor that is highly expressed in enteroendocrine cells, where its activation results in elevated 
intracellular Ca2+ concentrations and enhanced GLP-1 release [60]. Whilst an acute stimulation of 
GLP-1 secretion by SCFA is observed in primary colonic cultures, however, the potential importance 
of GPR43 or GPR41 dependent Gi activation remains uncertain and the effects of locally produced 
SCFA on enteroendocrine secretion in vivo are unclear. In intestinal organoids, SCFA also led to an 
increase in L-cell number [63], although the underlying pathway has not been established. Thus, 
although high fibre diets have been linked to elevated GLP-1 and PYY levels, the precise underlying 
pathways remain to be established.  
Indole is a microbial product of tryptophan metabolism that can rise to low millimolar 
concentrations in the colonic lumen, and has opposing short and longer term effects on GLP-1 
release [61]. Its acute effect is to raise intracellular Ca2+ and enhance GLP-1 secretion. This is brought 
about not via a specific indole receptor, but by the inhibitory action of indole on voltage gated 
potassium channels. Blocking K+ channels results in a widening of action potentials and consequent 
increased voltage gated Ca2+ entry. When indole is raised for an hour or more, however, we 
observed suppression of GLP-1 release, coinciding with impaired mitochondrial ATP generation. As 
for SCFA, the relative importance of the stimulatory and inhibitory effects of indole in vivo is not yet 
clear. 
Indole and SCFA contribute to a soup of microbially produced enteroendocrine cell modulators 
found in the colonic lumen. Together with bile acids, nutrients that have escaped absorption, and 
other products of microbial metabolism, they likely exert a complex mixture of effects on 
enteroendocrine cells in the local vicinity. The overall importance of these microbial products for gut 
hormone secretion is uncertain, but it is possible that they contribute to fasting gut hormone 
concentrations when nutrient stimuli are no longer dominant. There are a number of important 
questions still to be addressed, including which of the microbially-produced regulators wins out in 
vivo, whether the balance of activity is changed when the microbiome changes, and how the 
interplay between microbial metabolites and gut hormone secretion is modified by changes in 
dietary habits. 
Translational aspects – influence of diet, weight loss and surgery 
An important unanswered question is whether the responsiveness of the gut endocrine axis is 
significantly altered by longer term dietary changes. Data from human studies suggest that people 
with obesity have raised fasting GLP-1 and lower fasting PYY plasma concentrations [64, 65], but 
whether these changes reflect the influence of different diets or body weight/adiposity is not clear. 
We evaluated whether L-cell function was altered by high fat diet feeding in mice, and observed 
higher baseline GLP-1 secretion in primary intestinal cultures that mirrored the increase in plasma 
GLP-1 concentrations found in obese humans [66]. Additionally we observed a reduction in the 
expression of enteroendocrine markers in purified L-cells from the high fat fed group, suggesting 
that western-style diets might impair function of the GLP-1 axis.  
Complementing these findings, a recent study of people who had lost weight and then maintained a 
lower body weight for a year, interestingly found that post-prandial GLP-1 concentrations were 
elevated after maintained weight loss, suggesting that enteroendocrine cell function is restored by 
prolonged exposure to a healthy diet or healthy weight [67]. The idea that L-cell function can be 
impaired and repaired is supported by the rapid turnover of enteroendocrine cells, because any L-
cells damaged by diet or obesity will be fully replaced after a few days by a new population 
generated from the crypt stem cells. Unless the stem cell population has itself suffered any 
epigenetic or other modification, newly generated enteroendocrine cells should not carry any 
memory of historic dietary exposure. 
Activity of the gut endocrine axis is dramatically altered by bariatric surgery, and likely contributes to 
the beneficial effects of these procedures on appetite and type 2 diabetes [68]. Post prandial 
secretion of hormones that predominate in the distal gut, particularly GLP-1 and PYY, are elevated 
approximately 10-fold after surgery, whereas hormones from the proximal gut are less affected [69]. 
Evidence suggests that, at least in humans, the elevated GLP-1 concentrations enhance pancreatic 
insulin release, and that both GLP-1 and PYY suppress appetite [70, 71]. Findings from mouse 
models, however, suggest that additional factors, such as bile acids, contribute to the body weight 
reduction observed after bariatric surgery [72].  
GLP-1 based medications are already used clinically for the treatment of type 2 diabetes and obesity, 
and there are a number of ongoing initiatives to try to improve on the effectiveness of GLP-1 
receptor agonism by the co-activation of other hormone receptors, such as those for GIP, glucagon 
and PYY. Results from a number of preclinical trials suggest that co-targeting more than one gut 
hormone receptor can lead to enhanced metabolic and body weight responses.     
Conclusions 
The gut endocrine axis provides an interface with the outside world, enabling the body to develop 
coordinated metabolic responses to nutrient intake. Enteroendocrine cells have developed a variety 
of sensory machineries capable of detecting multiple different components of ingested food. 
Interestingly, however, enteroendocrine cells seem particularly tuned to respond to nutrient 
absorption, rather than the mere presence of nutrients in the gut lumen. This solution enables the 
body to mount responses to nutrients at the time when they arrive in the bloodstream.  
There is widespread hope that an increased understanding of the sensory mechanisms in gut 
endocrine cells will lead to new dietary or medicinal strategies to harness the body’s endogenous 
reserve of gut hormones, and lead to new strategies to mimic bypass surgery. Therapies that harness 
the enteroendocrine axis for the treatment of obesity and type 2 diabetes are already in widespread 
use, and the success of bariatric surgery has spurred the ongoing development of many more.  
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